P24941 (CDK2_HUMAN) Homo sapiens (Human)

Cyclin-dependent kinase 2 UniProtKBInterProSTRINGInteractive Modelling

298 aa; Sequence (Fasta) ; (Isoform 2); 18 identical sequences

Available Structures

425 Experimental Structures

DescriptionOligo-stateLigandsStructureRange
Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with ATP Heteromer
P20248;
ATP;MG;SGM;1-298
Assess
CDK2/CyclinA in complex with AZD5438 Heteromer
P30274;
FB8;1-298
Assess
Thr 160 phosphorylated CDK2 K89D, Q131E - human cyclin A3 complex with the inhibitor RO3306 Heteromer
P20248;
1RO;DMS;SGM;1-298
Assess
Structure of CDK2/cyclin A in complex with CAN508 Heteromer
P30274;
F18;1-298
Assess
CDK2/Cyclin A covalent complex with 6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-am… Heteromer
P20248;
55S;1-298
Assess
Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 3 Heteromer
P30274;
MFR;MG;SGM;1-298
Assess
Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor Heteromer
P30274;
T6Q;SGM;SO4;1-298
Assess
Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor variolin B Heteromer
P30274;
VAR;MG;SGM;1-298
Assess
CDk2/cyclinA in complex with DRB Heteromer
P30274;
RFZ;FMT;SGM;1-298
Assess
Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. Heteromer
P20248;
2WC;MG;1-298
Assess
Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor Heteromer
P20248;
T3C;SO4;SGM;1-298
Assess
CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX Heteromer
P20248;
ATP;1-298
Assess
Structure of CDK2/Cyclin A with PNU-292137 Heteromer
P20248;
SO4;292;1-298
Assess
Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 5 Heteromer
P30274;
MHR;MG;1-298
Assess
Structure of phopsho-CDK2-cyclin A in complex with an ATP-competitive inhibitor Heteromer
P20248;
6ZK;SGM;MG;1-298
Assess
CDK-2-Cyclin complex with indazole inhibitor 9 bound at its active site Heteromer
P20248;
GOL;EZV;SO4;1-298
Assess
Thr 160 phosphorylated CDK2 H84S, Q85M, Q131E - human cyclin A3 complex with the inhibitor RO3306 Heteromer
P20248;
1RO;MG;1-298
Assess
STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 Heteromer
P20248;
529;SO4;1-298
Assess
STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 Heteromer
P20248;
P48;1-298
Assess
CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2 Heteromer
P89883;
CL;1-298
Assess
Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor NU6271 Heteromer
P30274;
NU5;1-298
Assess
Optimisation of 6,6-Dimethyl Pyrrolo 3,4-c pyrazoles: Identification of PHA-793887, a Potent CDK In… Heteromer
P20248;
SO4;889;1-298
Assess
Crystal structure of the Cyclin A-CDK2-ORC1 complex Heteromer
P20248; Q13415;
PO4;1-298
Assess
PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A Heteromer
P20248;
MN;ATP;1-298
Assess
STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 Heteromer
P20248;
SBC;SO4;1-298
Assess
Structure of CDK2-CYCLIN A with a Pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor Heteromer
P20248;
WXV;SO4;1-298
Assess
Crystal structure apo CDK2/cyclin A Heteromer
P20248;
1-298
Assess
CDK2/CyclinA in complex with CGP74514A Heteromer
P30274;
23D;1-298
Assess
Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8 Heteromer
P30274;
RC8;1-298
Assess
Crystal Structure of the CDK2/Cyclin A complex with oxindole inhibitor Heteromer
P20248;
60K;DTT;1-298
Assess
THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR Heteromer
P20248;
107;1-298
Assess
STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO- 1H-PYRAZOLO[4,3-H] QUINAZ… Heteromer
P20248;
P49;1-298
Assess
Cdk2/CyclinA complexed with a imidazo triazin-2-amine Heteromer
P20248;
T2A;1-298
Assess
CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor Heteromer
P20248;
5BP;1-298
Assess
Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. Heteromer
P20248;
G6T;1-298
Assess
Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor roscovitine Heteromer
P30274;
RRC;SGM;1-297
Assess
Thr 160 phosphorylated CDK2 Q131E - human cyclin A3 complex with the inhibitor RO3306 Heteromer
P20248;
1RO;SGM;1-297
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-pu… Heteromer
P20248;
N76;SGM;MG;1-297
Assess
Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor Heteromer
P20248;
T3E;SGM;1-297
Assess
Thr 160 phosphorylated CDK2 Q131E - human cyclin A3 complex with ATP Heteromer
P20248;
MG;ATP;SGM;1-297
Assess
Thr 160 phosphorylated CDK2 H84S, Q85M, Q131E - human cyclin A3 complex with ATP Heteromer
P20248;
ATP;MG;1-297
Assess
The structural basis of CDK2 activation by cyclin E Heteromer
P24864;
1-297
Assess
Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with ATP Heteromer
P20248;
ATP;MG;SGM;1-297
Assess
Crystal structure of CDK2/cyclin E in complex with PF-06873600 Heteromer
P24864;
WG1;1-297
Assess
CDK2/CyclinA in complex with an 11-residue recruitment peptide from p27 Heteromer
P20248; P46527;
1-297
Assess
Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with the inhibitor NU6102 Heteromer
P20248;
4SP;1-297
Assess
CDK2/CyclinA in complex with an 11-residue recruitment peptide from p53 Heteromer
P04637; P20248;
1-297
Assess
Mechanism of CDK inhibition by active site phosphorylation: CDK2 Y15p T160p in complex with cyclin … Heteromer
P20248;
ATP;1-297
Assess
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGU… Heteromer
P20248;
4SP;SGM;1-297
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor Heteromer
P20248;
C94;1-297
Assess
Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with the inhibitor RO3306 Heteromer
P20248;
1RO;SGM;MG;1-297
Assess
Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with the inhibitor RO3306 Heteromer
P20248;
1RO;1-297
Assess
Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with the inhibitor NU6102 Heteromer
P20248;
4SP;SGM;1-297
Assess
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-N… Heteromer
P20248;
ST8;SGM;1-297
Assess
STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 Heteromer
P20248;
SO4;514;1-297
Assess
Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor N-&-N1 Heteromer
P30274;
NNN;SGM;1-297
Assess
Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design Heteromer
P20248;
X1N;1-297
Assess
Cdk2/Cyclin A complexed with a thiophene carboxamide inhibitor Heteromer
P20248;
BLZ;1-297
Assess
The X-ray co-crystal structure of human CDK2/CyclinE and Dinaciclib. Heteromer
P24864;
1QK;GOL;1-297
Assess
CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor Heteromer
P20248;
PO5;1-297
Assess
Crystal structure of SUN1-Speedy A-CDK2 Heteromer
O94901; Q5MJ70;
GOL;ZN;2-298
Assess
The crystal structure of CDK2 cyclin A in complex with a substrate peptide derived from CDC modifie… Heteromer
P20248; Q99741;
ATP;SO4;GOL;1-296
Assess
Structure of a pCDK2/CyclinA transition-state mimic Heteromer
P51943;
ADP;MG;MGF;CL;DTU;1-296
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6086 Heteromer
P20248;
6CP;1-296
Assess
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR Heteromer
P20248;
4SP;SGM;MG;1-296
Assess
CDK2/CyclinA in complex with SU9516 Heteromer
P30274;
SU9;1-296
Assess
Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. Heteromer
P20248;
75X;MG;1-296
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6102 Heteromer
P20248;
4SP;1-296
Assess
Structure of pCDK2/CyclinA bound to ADP and 2 Magnesium ions Heteromer
P51943;
ADP;MG;GOL;CL;1-296
Assess
REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors Heteromer
P20248;
MTZ;GVC;1-296
Assess
Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design Heteromer
P20248;
CK8;1-296
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU2058 Heteromer
P20248;
CMG;1-296
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-pu… Heteromer
P20248;
N20;SGM;MG;1-296
Assess
Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design Heteromer
P20248;
CK2;1-296
Assess
Structure of PCDK2/CYCLINA bound to ADP and 1 MAGNESIUM ION Heteromer
P51943;
ADP;MG;GOL;1-296
Assess
Structure of a pCDK2/CyclinA transition-state mimic Heteromer
P51943;
ADP;MG;MGF;CL; 10×GOL;1-296
Assess
PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX Heteromer
P20248;
ATP;MG;1-296
Assess
The structure of phospho-CDK2/cyclin A in complex with the inhibitor 4,5,6,7-tetrabromobenzotriazol… Heteromer
P20248;
TBS;1-296
Assess
Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design Heteromer
P20248;
CK7;1-296
Assess
THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A Heteromer
P20248;
UCN;1-296
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor Heteromer
P20248;
C95;1-296
Assess
Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Ile-Phe-NH2 Heteromer
P20248;
1-296
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-pu… Heteromer
P20248;
N41;SGM;MG;1-296
Assess
Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor Heteromer
P20248;
T7Z;SGM;1-296
Assess
Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. Heteromer
P20248;
SQ9;1-296
Assess
Cyclin A binding groove inhibitor Ac-Arg-Arg-Leu-Asn-(m-Cl-Phe)-NH2 Heteromer
P20248;
1-296
Assess
Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6094 Heteromer
P20248;
2A6;1-296
Assess
Thr 160 phosphorylated CDK2 - Human cyclin A3 complex with the inhibitor indirubin-5-sulphonate bou… Heteromer
P20248;
INR;1-296
Assess
CDK2/CyclinA in complex with Flavopiridol Heteromer
P30274;
F9Z;1-296
Assess
Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design Heteromer
P20248;
1-296
Assess
Cyclin A binding groove inhibitor Ace-Arg-Lys-Leu-Phe-Gly Heteromer
P20248;
1-296
Assess
Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Asn-(p-F-Phe)-NH2 Heteromer
P20248;
1-296
Assess
Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment sit… Heteromer
P20248;
MG;1-296
Assess
REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors Heteromer
P20248;
C35;1-296
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor Heteromer
P20248;
DT5;1-296
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor Heteromer
P20248;
C75;1-296
Assess
pCDK2/cyclin A in complex with MgADP, nitrate and peptide substrate Heteromer
P20248;
ATP;MG;NO3;GOL;1-296
Assess
Crystal structure of phospho-CDK2 Cyclin A in complex with a peptide containing both the substrate … Heteromer
P20248; Q99741;
ATP;MG;1-296
Assess
Crystal structure of human Cdk2-Spy1 complex Heteromer
Q5MJ70;
1-296
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor Heteromer
P20248;
C85;1-296
Assess
CDK2/CyclinA in complex with an 11-residue recruitment peptide from p107 Heteromer
P20248; P28749;
1-296
Assess
Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment sit… Heteromer
P20248;
1-296
Assess
Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. Heteromer
P20248;
4QE;1-296
Assess
Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design Heteromer
P20248;
1-296
Assess
Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design Heteromer
P20248;
CK4;1-296
Assess
Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design Heteromer
P20248;
MTW;1-296
Assess
Cyclin A binding groove inhibitor H-Cit-Cit-Leu-Ile-(p-F-Phe)-NH2 Heteromer
P20248;
1-296
Assess
CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2 Heteromer
Q16667;
MG;ATP;1-296
Assess
STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR Heteromer
P20248;
QQ2;SGM;MG;1-295
Assess
CDK2/Cyclin A in complex with compound 73 Heteromer
P20248;
72L;1-295
Assess
CDK2/cyclin A2 in complex with an imidazo[1,2-c]pyrimidin-5-one inhibitor Heteromer
P20248;
R7B;EDO;NA;1-294
Assess
Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor Heteromer
P20248;
T9N;SO4;1-294
Assess
Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. Heteromer
P20248;
JYM;DTT;1-294
Assess
Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor Heteromer
P30274;
TJF;1-294
Assess
CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1 Heteromer
P61024;
1-294
Assess
Crystal structure of human Cdk2-Spy1 complex Heteromer
Q5MJ70;
3-296
Assess
CDK2/CyclinA in complex with a 9 residue recruitment peptide from E2F Heteromer
P20248; Q01094;
1-293
Assess
CDK2/Cyclin A in complex with an 11-residue recruitment peptide from retinoblastoma-associated prot… Heteromer
P06400; P20248;
1-293
Assess
CDK2/cyclin A2 in complex with 3H-pyrazolo[4,3-f]quinoline-based derivative HSD1368 Heteromer
P20248;
T1T;NO3;SO4;1-293
Assess
CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR4455 Heteromer
P20248;
FCQ;EDO;CL;BR;PG4;SGM;PGE;1-290
Assess
CDK2/cyclin A2 in complex with open-ring 5-nitrosopyrimidine inhibitor LC436 Heteromer
P20248;
K4W;NA;GOL;1-290
Assess
Crystal structure of phospho-CDK2 in complex with Cyclin B Heteromer
P14635;
1-288
Assess
P27(KIP1)/CYCLIN A/CDK2 COMPLEX Heteromer
P20248; P46527;
SO4;13-298
Assess
Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: NEDD8-CUL1-RBX1-SKP… Heteromer
P0CG48; P20248; P46527; P61024; P62877; P63208; P68036; Q13309; Q13616; Q15843; Q9Y4X5;
ZN;SY8;13-298
Assess
Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: CUL1-RBX1-SKP1-SKP2… Heteromer
P20248; P46527; P61024; P63208; Q13309; Q13616;
13-298
Assess
Cdk2/cyclin A/p27-KID-deltaC Heteromer
P20248; P46527;
SO4;17-298
Assess
Crystal structure of human Cdk2-Spy1-P27 ternary complex Heteromer
P46527; Q5MJ70;
19-292
Assess
Structure of CDK2/cyclin A M246Q, S247EN Heteromer
P20248;
28-295
Assess
CDK2 in complex with FragLite37monomerHJK;1-298
Assess
CDK2 in complex with FragLite6monomerDMS;HGQ;1-298
Assess
CDK2 in complex with FragLite36monomerHGH;DMS;1-298
Assess
CDK2 in complex with FragLite34monomerDMS;HHB;1-298
Assess
CDK2 in complex with FragLite33monomerDMS;HH5;1-298
Assess
CDK2 in complex with FragLite38monomerHHW;EDO;1-298
Assess
CDK2 in complex with FragLite2monomerPYZ;1-298
Assess
CDK2 in complex with FragLite35monomerDMS;HGK;1-298
Assess
CDK2 in complex with FragLite13monomerHHN;1-298
Assess
CDK2 in complex with FragLite14monomerHGW;1-298
Assess
CDK2 in complex with FragLite2monomerHEW;1-298
Assess
CDK2 in complex with FragLite32monomer26D;1-298
Assess
Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitormonomerCK2;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomerSCF;1-298
Assess
CDK2 in complex with CGP74514AmonomerFC8;1-298
Assess
CCT068127 in complex with CDK2monomer8QT;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-Amino-6-(3'-methyl-2'-oxo)butoxypuri…monomerMBP;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer5SC;1-298
Assess
CDK2 in complex with inhibitor RC-3-89monomerEDO;X64;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer6SC;1-298
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer60K;GOL;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomerSC8;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomerSCE;1-298
Assess
CDK2 in complex with AZD5438monomerFB8;EDO;1-298
Assess
Crystal structure of the cdk2 in complex with aminopyrazole inhibitormonomer4CK;1-298
Assess
Crystal structure of the cdk2 in complex with aminopyrazole inhibitormonomer10K;1-298
Assess
Crystal structure of human CDK2 (unphosphorylated) in complex with PKF049-365monomer89E;1-298
Assess
Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitormonomer20K;ACT;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomerSC9;1-298
Assess
CDK2 in complex with inhibitor KVR-2-80monomerEDO;18Z;1-298
Assess
CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-b]PYRIDAZINEmonomerI1P;1-298
Assess
Crystal structure of the cdk2 in complex with aminopyrazole inhibitormonomer03K;1-298
Assess
CDK2 in complex with a disubstituted 4, 6-bis anilino pyrimidine CDK4 inhibitormonomerFAP;FCP;1-298
Assess
Crystal Structure of the Cdk2 in Complex with Aminopyrazole Inhibitormonomer09K;1-298
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomerLS5;NA;1-298
Assess
Crystal Structure of CDK2 in complex with compound 22monomer6QB;1-298
Assess
CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL]SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZIN…monomerGOL;7YG;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomerSCZ;1-298
Assess
Crystal structure of the cdk2 in complex with aminopyrazole inhibitormonomer11K;ACT;1-298
Assess
CDK2 with compound 14 inhibitor with carboxylatemonomerYOS;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomerSCW;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomerSCJ;1-298
Assess
Cdk2(F80C) with Covalent Adduct TK22 at F80CmonomerOY2;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer3SC;1-298
Assess
Crystal structure of a CDK inhibitor bound to CDK2monomer6AE;1-298
Assess
Cdk2(F80C) with Covalent Adduct TK37 at F80CmonomerOWN;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerLZD;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomerSCX;1-298
Assess
Crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitormonomer16K;1-298
Assess
CDK2 in complex with inhibitor L2monomerEDO;X11;PO4;1-298
Assess
Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitormonomer18K;ACT;1-298
Assess
Crystal structure of CDK2 processed with the CrystalDirect automated mounting and cryo-cooling tech…monomer1-298
Assess
Crystal structure of CDK2 in complex with 6-methoxy-7H-purine processed with the CrystalDirect auto…monomerSZL;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomerSCQ;1-298
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer61K;GOL;1-298
Assess
CDK2 in complex with inhibitor KVR-1-164monomerEDO;X87;1-298
Assess
CDK2 ternary complex with JWS648 and ANSmonomer2AN;JWS;1-298
Assess
CDK2 in complex with inhibitor KVR-1-160monomerEDO;X85;1-298
Assess
CDK2 in complex with DinaciclibmonomerEDO;1QK;1-298
Assess
Cdk2(F80C)monomer1-298
Assess
CDK2 in complex with FragLite16monomerHH8;1-298
Assess
CDK2 in complex with inhibitor SU9516monomerEDO;PO4;SU9;1-298
Assess
CDK2 in complex with inhibitor RC-2-21monomerZ68;1-298
Assess
CDK2 in complex with inhibitor RC-3-89monomerEDO;X64;1-298
Assess
CDK2 in complex with inhibitor JWS-6-76monomerEDO;X67;1-298
Assess
CDK2 in complex with inhibitor KVR-1-142monomerEDO;X6A;1-298
Assess
CDK2 in complex with inhibitor NSK-MC2-55monomerEDO;X14;1-298
Assess
CDK2 in complex with inhibitor KVR-1-140monomerEDO;XA0;1-298
Assess
CDK2 in complex with inhibitor KVR-1-156monomerEDO;24Z;1-298
Assess
CDK2 in complex with inhibitor L1monomerEDO;X07;1-298
Assess
CDK2 in complex with inhibitor KVR-1-75monomerEDO;X96;1-298
Assess
CDK2 in complex with inhibitor KVR-1-126monomerEDO;X72;1-298
Assess
CDK2 in complex with inhibitor RC-2-39monomer56Z;1-298
Assess
CDK2 in complex with inhibitor KVR-1-84monomerEDO;X65;1-298
Assess
CDK2 in complex with inhibitor RC-2-49monomer25Z;1-298
Assess
CDK2 in complex with inhibitor KVR-1-158monomerEDO;X84;1-298
Assess
CDK2 in complex with inhibitor KVR-2-92monomerEDO;Z14;1-298
Assess
CDK2 in complex with inhibitor RC-2-32monomer03Z;1-298
Assess
CDK2 in complex with inhibitor RC-2-34monomer04Z;1-298
Assess
CDK2 in complex with inhibitor KVR-1-190monomerEDO;X63;1-298
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer42K;GOL;1-298
Assess
CDK2 in complex with inhibitor KVR-1-162monomerEDO;X86;1-298
Assess
CDK2 in complex with inhibitor RC-2-22monomerO1Z;1-298
Assess
CDK2 in complex with inhibitor RC-2-33monomer20Z;1-298
Assess
CDK2 in complex with inhibitor KVR-1-154monomerEDO;22Z;1-298
Assess
Crystal structure of CDK2 IN complex with Inhibitor CVT-313monomerAJR;1-298
Assess
CDK2 in complex with inhibitor L3-3monomerPO4;Z19;1-298
Assess
CDK2 in complex with inhibitor JWS648monomerJWS;PO4;1-298
Assess
CDK2 in complex with inhibitor KVR-1-134monomerEDO;X76;1-298
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer62K;GOL;1-298
Assess
4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2…monomerF18;1-298
Assess
CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitormonomerBYP;BWP;GOL;1-298
Assess
Novel CDK-5 inhibitors - crystal structure of inhibitor EFQ with CDK-2monomerEFQ;1-298
Assess
Novel CDK-5 inhibitors - crystal structure of inhibitor EFP with CDK-2monomerEFP;1-298
Assess
Crystal structure of cdk2 with an aminoimidazo pyridine inhibitormonomer628;1-298
Assess
CDK2 in complex with inhibitor RC-2-88monomerEDO;26Z;1-298
Assess
CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(1,1-DIMETHYLETHYL)…monomer56H;1-298
Assess
CDK2 in complex with inhibitor L4-14monomerZ60;1-298
Assess
CDK2 in complex with inhibitor NSK-MC1-6monomerZ46;1-298
Assess
CDK2 in complex with inhibitor KVR-1-127monomerEDO;X73;1-298
Assess
HUMAN CYCLIN-DEPENDENT KINASE 2monomer1-298
Assess
CDK2 in complex with inhibitor RC-2-71monomerEDO;08Z;1-298
Assess
CDK2 in complex with two molecules of 8-anilino-1-naphthalene sulfonatemonomerEDO;2AN;1-298
Assess
Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitormonomer19K;1-298
Assess
Human CDK2 in complex with isopentenyladeninemonomerZIP;1-298
Assess
Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitormonomer2SC;1-298
Assess
CDK2 in complex with inhibitor RC-1-137monomerEDO;X35;1-298
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomerDT1;1-298
Assess
CDK2 in complex with inhibitor RC-2-132monomerX44;1-298
Assess
Structure of CDK2 in complex with a benzimidazopyrimidinemonomerACT;D6I;1-298
Assess
Modulating the interaction between CDK2 and Cyclin A with a Quinoline-based inhibitormonomer2KD;1-298
Assess
Cyclin Dependent Kinase 2 (CDK2) with diaminopyrimidine inhibitormonomerLIA;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerLZE;1-298
Assess
CDK2 in complex with inhibitor RC-2-74monomer09Z;1-298
Assess
CDK2 in complex with inhibitor RC-1-136monomerZ63;1-298
Assess
CDK2 in complex with inhibitor RC-2-13monomerEDO;X3A;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027monomerNW1;1-298
Assess
STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873monomerU73;1-298
Assess
CDK2 in complex with inhibitor RC-1-148monomerX36;1-298
Assess
CDK2 in complex with inhibitor KVR-1-102monomerEDO;X75;1-298
Assess
CDK2 in complex with inhibitor L3monomerX03;1-298
Assess
Human cyclin dependent kinase 2 (cdk2) complexed with indenopyraxole DIN-101312monomerD31;1-298
Assess
Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibit…monomerY8L;1-298
Assess
CDK2 in complex with inhibitor KVR-1-74monomerEDO;X9I;1-298
Assess
CDK2 in complex with inhibitor KVR-1-91monomerEDO;19Z;1-298
Assess
Human cyclin dependent kinase 2 (CKD2)complexed with DIN-232305monomerD05;1-298
Assess
CDK2 in complex with inhibitor L4-12monomer06Z;1-298
Assess
CDK2 in complex with inhibitor KVR-1-150monomerEDO;X62;1-298
Assess
CDK2 in complex with inhibitor RC-3-96monomerEDO;99Z;1-298
Assess
CDK2 in complex with inhibitor L4monomerEDO;X02;1-298
Assess
CDK2 in complex with inhibitor L2-2monomerEDO;X0A;PO4;1-298
Assess
Human cyclin dependent kinase 2 (CDK2) complexed with DPH-042562monomerD42;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerLZB;1-298
Assess
CDK2 in complex with inhibitor RC-2-23monomer02Z;1-298
Assess
CDK2 in complex with inhibitor RC-2-143monomerZ71;1-298
Assess
CDK2 in complex with 3 molecules of 8-anilino-1-naphthalene sulfonatemonomerEDO;2AN;1-298
Assess
CDK2 in complex with inhibitor JWS-6-260monomerEDO;X01;1-298
Assess
CDK2 in complex with an imidazole piperazinemonomerIM9;1-298
Assess
CDK2 in complex with inhibitor KVR-2-88monomerEDO;Z04;1-298
Assess
CDK2 in complex with inhibitor L3-4monomerZ30;1-298
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer45K;GOL;1-298
Assess
CDK2 in complex with inhibitor RC-1-135monomerZ62;1-298
Assess
CDK2 in complex with inhibitor KVR-1-67monomerEDO;X88;1-298
Assess
Crystal structure of CDK2 in complex with 2,4,6-trioxo-1-phenyl- hexahydropyrimidine-5-carboxamide …monomerRJI;1-298
Assess
CDK2 in complex with inhibitor RC-2-12monomerX46;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerLZC;1-298
Assess
Structure of CDK2 in complex with an imidazolyl pyrimidine, compound 5bmonomerFRT;1-298
Assess
HUMAN CYCLIN-DEPENDENT KINASE 2monomerMG;ATP;1-298
Assess
CDK-2 with indazole inhibitor 17 bound at its active sitemonomerEZR;1-298
Assess
CDK2 in complex with inhibitor L2-5monomerEDO;X06;PO4;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519)…monomerGOL;LZ2;1-298
Assess
Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-Amino-6-[(R)-pyrrolidino-5'…monomerUN4;1-298
Assess
Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibit…monomerCDK;1-298
Assess
Crystal structure of a benzthiophene inhibitor bound to human Cyclin-dependent Kinase-2 (CDK-2)monomerB98;1-298
Assess
HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINEmonomerBRY;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerLZA;1-298
Assess
CDK2 in complex with inhibitor RC-2-40monomer27Z;1-298
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomerDT2;1-298
Assess
CDK2 in complex with inhibitor YL1-038-31monomer0BX;PO4;1-298
Assess
CDK2 in complex with inhibitor KVR-1-78monomerEDO;X4B;1-298
Assess
Human CDK2 in complex with olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kina…monomerCK9;1-298
Assess
CDK2 in complex with inhibitor RC-3-86monomer21Z;1-298
Assess
CDK2 in complex with inhibitor RC-2-38monomerEDO;X40;1-298
Assess
CDK2 in complex with inhibitor RC-2-135monomerX6B;1-298
Assess
CDK2 in complex with inhibitor KVR-1-9monomerEDO;Z02;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058monomerCMG;1-298
Assess
CDK2 in complex with inhibitor RC-2-35monomerX43;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,5-Dichloro-thiophen-3-yl)-pyrimid…monomerCK1;1-298
Assess
CDK2 in complex with inhibitor NSK-MC1-12monomerEDO;X19;1-298
Assess
APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2monomer1-298
Assess
CDK2 in complex with inhibitor KVR-1-124monomerEDO;X69;1-298
Assess
Crystal Structure of CDK2 in complex with pan-CDK Inhibitormonomer3I6;1-298
Assess
Structure of CDK2 in complex with a Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine.monomer404;1-298
Assess
The structure of cyclin-dependent kinase 2 (CDK2) in complex with 4-[(6-amino-4-pyrimidinyl)amino]b…monomerU55;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-Amino-4-methyl-thiazol-5-yl)-pyr…monomerCK7;1-298
Assess
STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032monomerU32;1-298
Assess
CDK2 in complex with SUNITINIBmonomerB49;EDO;1-298
Assess
CDK-2 with indazole inhibitor 9 bound at its active sitemonomerEZV;1-298
Assess
Crystal structure of human CDK2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitormonomerCT7;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINEmonomerSTU;1-298
Assess
Human cyclin dependent kinase 2 complexed with the CDK4 inhibitormonomer1CD;1-298
Assess
CDK2 in complex with Cpd14 (5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-…monomerN14;1-298
Assess
Human Cyclin Dependent Kinase 2 (CDK2) bound to azabenzimidazole derivativemonomer1N3;1-298
Assess
Human cyclin dependent kinase 2 (CDK2) complexed with DIN-234325monomerD23;1-298
Assess
CDK2 in complex with inhibitor RC-2-73monomerEDO;12Z;1-298
Assess
HUMAN CYCLIN-DEPENDENT KINASE 2monomerMG;ATP;1-298
Assess
CDK2 in complex with staurosporinemonomerSTU; 16×EDO;1-298
Assess
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMIN…monomerLS3;1-298
Assess
CDK2 in complex with inhibitor RC-2-72monomer07Z;1-298
Assess
CDK2 in complex with inhibitor RC-1-132monomerZ31;1-298
Assess
CDK2 in complex with NSC 134199monomer0S0;EDO;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerLZ3;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerLZ5;1-298
Assess
CDK2 in complex with inhibitor RC-2-36monomerEDO;X42;1-298
Assess
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AM…monomerLS4;1-298
Assess
CDK2 complex with a 4-alkynyl oxindole inhibitormonomerFMD;1-298
Assess
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[…monomerLS2;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITORmonomer1PU;1-298
Assess
Apo CDK2 crystallized from JeffaminemonomerEDO;1-298
Assess
Crystal structure of CDK2 with inhibitormonomerPM1;1-298
Assess
Crystal structure of CDK2 in complex with pyrazolopyrimidine inhibitormonomerACT;PDY;1-298
Assess
Crystal structure of cyclin-dependent kinase 2 (cdk2-wt) complex with (2s)-n-(5-(((5-tert-butyl-1,3…monomer1YG;1-298
Assess
CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]M…monomerLS5;1-298
Assess
CDK2 in complex with inhibitor JWS-6-52monomerX66;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerGOL;LZ1;1-298
Assess
CDK2 in complex with inhibitor RC-1-138monomer50Z;1-298
Assess
Crystal structure of CDK2 with SAR60, an aminoindazole type inhibitormonomerA28;1-298
Assess
Crystal structure of (R,S)-S-{4-[(5-Bromo-4-{[(2R,3R)-2-hydroxy-1-methylpropyl]oxy}- pyrimidin-2-yl…monomer6AF;1-298
Assess
Crystal structure of BAY 1000394 (Roniciclib) bound to CDK2monomerR0N;1-298
Assess
Structure of CDK2 in complex with an imidazolyl pyrimidine, compound 5cmonomerFRV;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL BmonomerPVB;EDO;1-298
Assess
CDK2 ternary complex with SU9516 and ANSmonomerEDO;SU9;2AN;1-298
Assess
CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H-PURIN-2- YLAMINE AND MONOMERIC CDK2monomerN69;1-298
Assess
HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINEmonomerHMD;EDO;1-298
Assess
CDK2 in complex with inhibitor YL5-083monomer0BY;PO4;1-298
Assess
HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160monomerMG;ATP;1-298
Assess
CDK2 in complex with inhibitor RC-2-142monomerZ67;1-298
Assess
Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-Amino-6-[cyclohex-3-enyl]me…monomer207;1-298
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomerCT8;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerLZ9;1-298
Assess
Fragment-Based Discovery of the Pyrazol-4-yl urea (AT9283), a Multi- targeted Kinase Inhibitor with…monomerL0F;1-298
Assess
CDK2 in complex with the imidazole pyrimidine amide, compound (S)-8bmonomerACT;I19;1-298
Assess
Crystal structure of human CDK2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitormonomerCT9;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerLZ8;1-298
Assess
CDK2 complexed with N-methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonam…monomerLS1;1-298
Assess
THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-6,7-DIMETHOX…monomerDTQ;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerGOL;LZ4;1-298
Assess
Structure of CDK2 with a 3-hydroxychromonesmonomer371;1-298
Assess
Crystal structure of human CDK2 in complex with the inhibitor olomoucine.monomerOLO;1-298
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitormonomerC53;CL;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITORmonomer2PU;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerLZ7;1-298
Assess
THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITORmonomer106;1-298
Assess
screening for fragment binding by X-ray crystallographymonomerCIG;1-298
Assess
Structure of CDK2 complexed with PNU-181227monomerN5B;1-298
Assess
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519…monomerLZM;1-298
Assess
Crystal structure of CDK2 with SAR57, an aminoindazole type inhibitormonomerA27;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrim…monomerCK8;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidi…monomerCK2;1-298
Assess
Crystal structure of CDK2 IN complex with Inhibitor NU-6140monomerAQG;1-298
Assess
Crystal structure of CDK2 with a 2-aminopyrimidine compoundmonomerPMU;1-298
Assess
Crystal structure of a 3-aminoindazole compound with CDK2monomer740;1-298
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitormonomerC96;1-298
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomerDT4;1-298
Assess
CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITORmonomer3FP;1-298
Assess
Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified thr…monomerHDU;1-298
Assess
Human cyclin-dependent kinase 2 in complex with roscovitinemonomerRRC;1-298
Assess
Crystal structure of CDK2 with SAR37, an aminoindazole type inhibitormonomerA07;1-298
Assess
CDK2 in complex with staurosporine and 2 molecules of 8-anilino-1-naphthalene sulfonic acidmonomerSTU;2AN;EDO;1-298
Assess
Crystal Structure of CDK2 in complex with Macrocyclic AminopyrimidinemonomerPY8;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2,4-Dimethyl-thiazol-5-yl)-pyrimid…monomerCK4;1-298
Assess
The structure of cyclin dependent kinase 2 (CKD2) with a trisubstituted naphthostyril inhibitormonomer5BN;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-Methyl-2-methylamino-thiazol-5…monomerCK6;1-298
Assess
Crystal Structure of Human Cyclin-Dependent Kinase 2 Complexed with a Nucleoside InhibitormonomerSU9;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrim…monomerCK5;1-298
Assess
HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-…monomerRYU;1-298
Assess
CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717monomerI17;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITORmonomer1PU;1-298
Assess
HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)pyrimi…monomerCK3;1-298
Assess
CDK2 in complex with FragLite1monomerBYZ;2-298
Assess
CDK2 in complex with NSC 35676monomer12×EDO;TIY;2-298
Assess
Crystal structure of CDK2 in complex with 6-chloro-7H-purine processed with the CrystalDirect autom…monomerES4;2-298
Assess
Crystal structure of CDK2 in complex with 7-hydroxy-4-(morpholinomethyl)chromen-2-one processed wit…monomerWY3;2-298
Assess
CDK2 in complex with NSC 111848monomer3TI;EDO;2-298
Assess
DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGNmonomerMTW;1-297
Assess
CDK2 in complex with FragLite7monomerDMS;HHQ;1-296
Assess
CDK2 in complex with FragLite31monomerHHT;1-296
Assess
Crystal structure of the cdk2 in complex with aminopyrazole inhibitormonomer1CK;NA;1-296
Assess
Crystal structure of apo CDK2monomer1-296
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer46K;1-296
Assess
Crystal structure of the cdk2 in complex with oxindole inhibitormonomer48K;1-296
Assess
Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified thr…monomerHDT;3-298
Assess
Crystal structure of CDK2 in complex with N-(9H-purin-6-yl)thiophene- 2-carboxamide processed with …monomerZXC;3-298
Assess
Cdk2(F80C, C177A) with covalent adduct at C80monomerAEQ;1-296
Assess
Crystal structure of CDK2 in complex with inhibitor BS-194monomerNS9;3-298
Assess
CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitormonomerGOL;FAL;FBL;1-296
Assess
CDK2 in complex with a disubstituted 4, 6-bis anilino pyrimidine CDK4 inhibitormonomerMFP;MFQ;1-296
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomerDT5;1-296
Assess
Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified thr…monomerHDY;1-296
Assess
Crystal structure of CDK2 in complex with inhibitor ICEC0942monomerACT;I74;3-298
Assess
Crystal structure of CDK2 in complex with inhibitor ICEC0943monomerI73;3-298
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomerCT6;1-296
Assess
Human CDK2 with type II inhibitormonomerLQ5;1-296
Assess
CDK2 in complex with LuciferinmonomerESJ;3-298
Assess
Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitormonomer4SP;1-296
Assess
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitormonomerC62;1-296
Assess
Cdk2(WT) covalent adduct with D28 at C177monomer9YZ;2-296
Assess
CDK2 with EGFR inhibitor compound 8monomerACT;3QS;1-295
Assess
Cdk2(WT) with covalent adduct at C177monomerAAK;2-296
Assess
Cdk2(F80C, C177A) covalent adduct with C37 at F80Cmonomer9Z2;4-298
Assess
Structure of cyclin-dependent kinase 2 with small-molecule ligand 4- fluorobenzoic acid (AT222) in …monomer1Y6;ACE;1-295
Assess
Structure of cyclin-dependent kinase 2 with small-molecule ligand 3-(4,7-dichloro-1H-indol-3-yl)pro…monomerMFZ;1-294
Assess
The structure of cyclin dependent kinase 2 (CKD2) with a pyrazolobenzodiazepine inhibitormonomer2BZ;1-294
Assess
Aerosol-soaked human cdk2 crystals with StaurosporinemonomerSTU;EDO;1-294
Assess
Cdk2(F80C, C177A) with covalent ligand at F80Cmonomer9ZB;2-294
Assess
CDK2 in complex with a Luciferin derivatemonomerWG8;3-295
Assess
Crystal structure of CDK2 in complex with 2-imidazol-1-yl-1H- benzimidazole processed with the Crys…monomer5JE;2-294
Assess

1 Homology model

Oligo-stateLigandsQMEANDisCoTemplateRangeSeq id (%)
monomerCK2;0.862c5o.1.A1-295
100.00
Assess

1 Homology model built on isoform sequence

IsoformOligo-stateLigandsQMEANDisCoTemplateRangeSeq id (%)
Isoform 2monomerCK2;0.792c5o.1.A1-261
89.35
Assess

Alignments